More recently, it was shown that stromal PKC inhibition, by a chimeric peptide HKPS or the conventional inhibitors Enzastaurin or Staurosporine, increased the chemosensitivity to drug treatment in B-ALL [16] and CLL [17]. This evidence concerns the gene PRRT2 and precursor B-cell acute lymphoblastic leukemia.